high-risk non-ST-segment elevation acute coronary syndromes (NSTE-ACS)
Conditions
Interventions
Group 2:Received tirofiban with the guidewire crossing the coronary lesion. Tirofiban was administrated as a bolus dose of 10ug/kg per 3 min, following by an infusion of 0.15ug/kg/min up to 24-36h aft
Group 1:Received tirofiban within 4-6h before coronary angiography. Tirofiban was administrated as a bolus dose of 10ug/kg per 3 min, following by an infusion of 0.15ug/kg/min up to 24-36h after PCI.
Sponsors
Beijing Anzhen Hospital, Capital University of Medical Science
Eligibility
Sex/Gender
All
Age
25 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients were considered eligible for the enrolment if they fulfilled all of the following criteria: (1) male or female patients range 25 to 80 years; (2) All of high-risk NSTE-ACS patients were required to undergo PCI within 48h of admission; (3) Written informed consent about tirofiban was obtained from all patients before PCI. High-risk NSTE-ACS was including either: 1. non-ST-segment elevation acute myocardial infarction; or 2. unstable angina associated with at least one of the following findings: (1) repeated angina at rest within 48h; (2) ischemic electrocardiographic changes consisting of ST depression >=0.1mV or transient(=0.1mV; (3) the history of prior PCI within 6 months; (4) known high-risk coronary lesions through coronary angiography, including left main disease, three-vessel disease, bifurcation disease, thrombotic disease and slowly flowing disease.
Exclusion criteria
Exclusion criteria: (1) ST-segment-elevation acute myocardial infarction; (2) patients undergoing emergency PCI after medicine treatment; (3) cardiogenic shock; (4) cardiac function range from NYHA III to NYHA IV; (5) uncontrolled hypertension (blood pressure >160/100mmHg); (6) renal insufficiency (the value of serum creatinine more than twice upper normal value), hepatic inadequacy (the value of transaminase more than twice upper normal value); (7) active bleeding, the history of major operation/external injury within three mouths, the history of cerebral vascular accident within six mouths; (8) severe hemophthisis (hemoglobin<90g/l) or the history of thrombopenia (thrombocyte<90×109/L); (9)other conditions were not suitable to be selected.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of 24h, 3d, 7d, 30d and 180d major adverse cardiovascular events (MACE) after PCI;the incidence of bleeding complications and thrombocytopenia from the beginning of tirofiban administration;cTnI; | — |
Countries
China
Contacts
Public ContactXie Ying
Outcome results
None listed